MG
MGTX
Methodology breakdown computing — it will appear here on its own.
MeiraGTx Holdings plc (MGTX) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-25). See the full ratio breakdown and business-activity screen below for the reasoning.
🕌 In-house Compliance Research
Computing the full ratio and business-activity breakdown for MGTX — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 40.90 | NEUTRAL |
| Stochastic %K (14) | 7.69 | BUY |
| CCI (20) | -155.33 | BUY |
| Williams %R (14) | -92.31 | BUY |
| MACD (12,26,9) | -0.21 | SELL |
| ROC (10) | -11.74 | SELL |
| Momentum (10) | -1.71 | SELL |
| EMA (10) | 13.64 | SELL |
| SMA (10) | 13.75 | SELL |
| EMA (20) | 13.66 | SELL |
| SMA (20) | 13.98 | SELL |
| EMA (30) | 13.48 | SELL |
| SMA (30) | 13.50 | SELL |
| EMA (50) | 13.00 | SELL |
| SMA (50) | 13.21 | SELL |
| EMA (100) | 11.90 | BUY |
| SMA (100) | 11.60 | BUY |
| EMA (200) | 10.43 | BUY |
| SMA (200) | 9.80 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
About MeiraGTx Holdings plc
Healthcare · Biotechnology
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
Background via Yahoo Finance — informational, not part of the verdict.
🟠 NOT YET
The main driver: insider selling on the open market. More negatives than positives right now. The setup isn't ready — check back when the trend or RSI changes.
Scores: 1 bullish / 2 bearish
Weak — low conviction, small size or skip
SMC — Top Down
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 62 |
| ⏰ 4H | BEARISH | 37 |
| 🕐 1H | RANGING | 98 |
| ⏱ 15-Min | BEARISH | 130 |
| ⏲ 5-Min | BEARISH | 234 |
Momentum & Volume
Peer Movement
Peer movement computing — it will appear here on its own.
Insider Activity (90d)
CLUSTER SELL 0 buys · 3 sells
Recent: Giroux Richard sold 908530 sh @ $12.51 (2026-07-21); Naylor Stuart sold 640846 sh @ $14.90 (2026-07-07); Naylor Stuart sold 665958 sh @ $13.86 (2026-07-07)
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.